{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-004136","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-08-14T13:00:38+00:00","discovered_at":"2026-08-14T13:02:01.340343+00:00","generated_at":"2026-08-14T13:02:11.477080+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silexion Q2 net loss widens to $3.6M; Phase 2/3 trial initiated","bullets":["Q2 net loss $3.6M vs $2.5M YoY; R&D up 120% to $2.2M on trial prep.","Six-month net loss $6.3M vs $4.2M; cash $2.2M at June 30, down from $6.0M.","Closed Aug 13 public offering gross $2.5M, net $2.1M; equity est. $3.2M, restoring Nasdaq compliance.","Phase 2/3 SIL204 trial initiated July 29 at Tel Aviv Sourasky; approvals from Germany BfArM and Israel.","1-for-10 reverse split May 28, 2026; preclinical data supports immune-sensitization across 4 KRAS mutations."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-004136","json":"https://secwatch.observer/filing/0001178913-26-004136.json","markdown":"https://secwatch.observer/filing/0001178913-26-004136.md","text":"https://secwatch.observer/filing/0001178913-26-004136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004136/0001178913-26-004136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004136/zk2635972.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T13:02:11.477080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}